CC
AGIO icon

Cannell & Co’s Agios Pharmaceuticals AGIO Stock Holding History

Cannell & Co’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-48,485
Closed -$3.74M – 248
2018
Q3 		$3.74M Buy
+48,485
New +$3.9M 0.13% 120
2016
Q4 		– Sell
-14,700
Closed -$776K – 250
2016
Q3 		$776K Hold
14,700
– – 0.03% 183
2016
Q2 		$616K Sell
14,700
-24,940
-63% -$1.23M 0.02% 193
2016
Q1 		$1.61M Hold
39,640
– – 0.06% 147
2015
Q4 		$2.57M Sell
39,640
-179,215
-82% -$11.8M 0.08% 131
2015
Q3 		$15.4M Buy
218,855
+64,100
+41% +$6.27M 0.5% 56
2015
Q2 		$17.2M Buy
+154,755
New +$16.7M 0.49% 55

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cannell & Co's AGIO Position: Q4 2018 in Review

Cannell & Co sold out of Agios Pharmaceuticals (AGIO) in Q4 2018, closing a stake of 48,485 shares — an estimated $3.74M sold.

Cannell & Co first reported a position in AGIO in Q2 2015 and held it in 7 quarters. The position peaked at $17.2M in Q2 2015. 196 funds tracked by Wall St. Rank hold AGIO as of Q4 2018.

  • Cannell & Co reported no remaining Agios Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Cannell & Co sold 48,485 Agios Pharmaceuticals shares in Q4 2018, an estimated $3.74M.
  • Cannell & Co first reported a position in Agios Pharmaceuticals in Q2 2015 and held it in 7 quarters.
  • Cannell & Co's Agios Pharmaceuticals position peaked at $17.2M in Q2 2015.
  • 196 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2018.

Based on Cannell & Co's 13F filing for Q4 2018, filed 11 Feb 2019.